Last reviewed · How we verify

NCT05559918: DAPT-FOR-REAL

Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting

Recruiting now Last updated 24 April 2024
What this trial tests

trial in Coronary Artery Disease in 1,462 participants. Currently enrolling.

Timeline
1 October 2022
Primary endpoint
30 July 2025
31 December 2025

Quick facts

Lead sponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,462
Start date1 October 2022
Primary completion30 July 2025
Estimated completion31 December 2025
Sites2 locations across Netherlands

Conditions studied

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the safety and efficacy of in-laboratory clopidogrel loading dose administration before ad-hoc PCI versus clopidogrel preloading treatment in patients planned for diagnostic angiography with optional ad-hoc PCI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05559918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing